Two TRK inhibitors, larotrectinib and entrectinib have shown durable antitumor activity in clinical trials of TRK fusion‐positive cancer patients14, 15, 16 and have received regulatory approval in many countries including the United States, Europe, and Japan.17, 18. The gene discussed is TPM3; the disease is cancer.